Tissue Phenomics Blog

5B_Her2-classified.jpg

Posts by Topic

see all

Topics:  Immunotherapy, tissue phenomics, tissue biomarkers, cancer immunotherapy, diagnostics, tissue-based diagnostics, io-panel

The Power of Predictive Quantitative Tissue-Based Diagnostics in Cancer Immunotherapy

Nov 21, 2017 8:00:00 AM

The American Society of Clinical Oncology named Immunotherapy 2.0 “Advance of the Year” at its 2017 Annual Meeting in Chicago, IL. This recognition comes after decades of incremental progress in our understanding of how the human immune system interacts with cancerous lesions. It also is the culmination of recent successes with checkpoint inhibitor therapy that promised dramatic changes in clinical practice and the approach to cancer treatment. What started with cutaneous melanoma in 2011 is now rapidly showing remarkable results also in other
cancer types. Just over the past year, the Food and Drug Administration (FDA) approved the use of checkpoint inhibitors in five additional cancer indications: lung, head and neck, bladder, kidney, and classical Hodgkin lymphoma.

Read More

Topics:  image analysis, personalized medicine, biomarker, immuno-oncology, tissue diagnostics, companion diagnostics, tissue biomarkers, diagnostics, diagnostic test, precision medicine, biomarker signature

3 ways tissue image analysis will shape the future of cancer treatment with immunotherapies

Nov 7, 2016 1:00:00 AM

As healthcare continues its transition towards precision medicine, physicians are eager to maximize both the quantity and quality of data obtained from their patients’ tissue samples.  In the current “one drug, one test” paradigm, physicians struggle to balance the number of tests required to make a treatment decision with the limited amount of tissue that is available.  Further complicating treatment decisions is the use of imperfect biomarkers associated with targeted therapies, as the patients who are identified to be ideal candidates for a targeted therapy respond only some of the time while patients who are not expected to respond do.  This dilemma is of great concern for those who are responsible for paying for these expensive therapies - payers and patients – who would like to avoid unnecessary expenses for drugs that may not work and possibly cause debilitating side effects.  Of course, of even greater concern is helping the patient identify the best therapeutic option that allows them the best opportunity to treat their disease and maximize their quality and quantity of life.

Read More

Topics:  drug development, tissue phenomics, biomarker expression, biomarker datafication, Definiens, biomarker screening, tissue biomarkers

Biomarker Selection to Accelerate Clinical Development Planning

Jul 7, 2015 9:30:00 AM

Biomarker projects are critical to drug development programs and demonstrating the medical value of therapies. In the planning phase of clinical development, researchers are often looking to achieve the following:

• Clinical researchers want a good understanding of the expected costs of a therapy program and the timelines involved.
• Clinical researchers want to know as early as possible which biomarker and indication combination works best to advance into clinical trials.

When you have multiple potential biomarkers and indications to evaluate for clinical development, you require flexible and fast screening projects to characterize the expression of specific markers in different tumor tissue.

Read More